- HeartBeam ( NASDAQ: BEAT ) is trading 54% higher premarket after it received patent for a 12-lead electrocardiogram (ECG) patch monitor to detect acute coronary syndrome and cardiac arrhythmia by the United States Patent and Trademark Office.
- The company expects its ECG device to detect ACS diagnosis including myocardial infarction (heart attack) and angina.
- The newly issued patent expands on the HeartBeam’s previously granted US patent for a 12-lead ECG patch monitor technology.
- The patch patent follows HeartBeam’s already granted core patents for remote detection of heart attacks.
- Stock has been down ~66% YTD.
For further details see:
HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks